O'Day Daniel Patrick sold $2.2M of GILD

The FDA approved several breast cancer treatments in 2026, including Daiichi Sankyo's fam-trastuzumab deruxtecan for early-stage HER2-positive breast cancer, datopotamab deruxtecan for triple-negative breast cancer, Gilead Sciences' sacituzumab govitecan for first-line TNBC, Pfizer's palbociclib for maintenance therapy, and AstraZeneca's camizestrant for HR-positive, HER2-negative advanced breast cancer.

Gilead Sciences and Vir Biotechnology agreed to collaborate on developing T-cell engager therapies for solid tumors. Gilead will pay $90m upfront, including $65m in cash and $25m in equity, with up to $1.74bn in potential milestones. Gilead will lead development and commercialization, using Vir's PRO-XTEN technology and AI platform. This follows their 2021 hepatitis B drug collaboration and Vir's recent deal with Astellas.

Vir Biotechnology (VIR) and Gilead Sciences (GILD) have partnered to develop cancer immunotherapies. Vir will receive up to $135M upfront, including $65M cash and a $25M equity investment, with potential future payments of $1.74B. Vir's PRO-XTEN technology aims to reduce side effects and improve targeting. VIR is down 0.75%, GILD up 2.18%.

Vir Biotechnology and Gilead Sciences agreed to collaborate on cancer therapies for solid tumors, with a deal potentially worth up to $1.88 billion. Vir will receive $90 million upfront and could earn additional milestone payments and royalties. The partnership focuses on developing three drug candidates using Vir's technologies. Vir shares rose over 10% in premarket trading.

Vir Biotechnology (VIR) shares rose 10% premarket after a licensing deal with Gilead (GILD) for cancer drug development, potentially worth $1.9B. The agreement involves Vir's PRO-XTEN technology.

Vir Biotechnology (VIR) and Gilead Sciences (GILD) announced a collaboration to develop cancer therapies. VIR will receive $90M upfront, with potential milestones up to $1.74B. VIR will handle discovery, while GILD will develop and commercialize the therapies. The deal focuses on T-cell engagers targeting solid tumors.